Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 265

1.

Wearing-off at the end of natalizumab dosing intervals is associated with low receptor occupancy.

Bringeland GH, Blaser N, Myhr KM, Vedeler CA, Gavasso S.

Neurol Neuroimmunol Neuroinflamm. 2020 Feb 4;7(3). pii: e678. doi: 10.1212/NXI.0000000000000678. Print 2020 May 4.

2.

Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk.

International Multiple Sclerosis Genetics Consortium. Electronic address: chris.cotsapas@yale.edu; International Multiple Sclerosis Genetics Consortium.

Cell. 2020 Jan 23;180(2):403. doi: 10.1016/j.cell.2020.01.002. No abstract available.

3.

The association between exposure to interferon-beta during pregnancy and birth measurements in offspring of women with multiple sclerosis.

Burkill S, Vattulainen P, Geissbuehler Y, Sabido Espin M, Popescu C, Suzart-Woischnik K, Hillert J, Artama M, Verkkoniemi-Ahola A, Myhr KM, Cnattingius S, Korhonen P, Montgomery S, Bahmanyar S.

PLoS One. 2019 Dec 30;14(12):e0227120. doi: 10.1371/journal.pone.0227120. eCollection 2019.

4.

Safety and efficacy of autologous hematopoietic stem cell transplantation for multiple sclerosis in Norway.

Kvistad SAS, Lehmann AK, Trovik LH, Kristoffersen EK, Bø L, Myhr KM, Torkildsen Ø.

Mult Scler. 2019 Dec 13:1352458519893926. doi: 10.1177/1352458519893926. [Epub ahead of print]

PMID:
31833798
5.

Gut microbiota composition during a 12-week intervention with delayed-release dimethyl fumarate in multiple sclerosis - a pilot trial.

Storm-Larsen C, Myhr KM, Farbu E, Midgard R, Nyquist K, Broch L, Berg-Hansen P, Buness A, Holm K, Ueland T, Fallang LE, Burum-Auensen E, Hov JR, Holmøy T.

Mult Scler J Exp Transl Clin. 2019 Nov 15;5(4):2055217319888767. doi: 10.1177/2055217319888767. eCollection 2019 Oct-Dec.

6.

Fingolimod downregulates brain sphingosine-1-phosphate receptor 1 levels but does not promote remyelination or neuroprotection in the cuprizone model.

Nystad AE, Lereim RR, Wergeland S, Oveland E, Myhr KM, Bø L, Torkildsen Ø.

J Neuroimmunol. 2020 Feb 15;339:577091. doi: 10.1016/j.jneuroim.2019.577091. Epub 2019 Oct 31.

PMID:
31739156
7.

Serum NFL levels should be used to monitor multiple sclerosis evolution - No.

Myhr KM, Torkildsen Ø.

Mult Scler. 2020 Jan;26(1):19-21. doi: 10.1177/1352458519872891. Epub 2019 Oct 18. No abstract available.

PMID:
31625829
8.

The Norwegian translation of the brief international cognitive assessment for multiple sclerosis (BICAMS).

Skorve E, Lundervold AJ, Torkildsen Ø, Myhr KM.

Mult Scler Relat Disord. 2019 Nov;36:101408. doi: 10.1016/j.msard.2019.101408. Epub 2019 Sep 21.

PMID:
31610403
9.

Validation of the multiple sclerosis diagnosis in the Norwegian Patient Registry.

Benjaminsen E, Myhr KM, Grytten N, Alstadhaug KB.

Brain Behav. 2019 Nov;9(11):e01422. doi: 10.1002/brb3.1422. Epub 2019 Oct 4.

10.

Risk of cancer among multiple sclerosis patients, siblings, and population controls: A prospective cohort study.

Grytten N, Myhr KM, Celius EG, Benjaminsen E, Kampman M, Midgard R, Vatne A, Aarseth JH, Riise T, Torkildsen Ø.

Mult Scler. 2019 Oct 1:1352458519877244. doi: 10.1177/1352458519877244. [Epub ahead of print]

PMID:
31573834
11.

Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk.

International Multiple Sclerosis Genetics Consortium. Electronic address: chris.cotsapas@yale.edu; International Multiple Sclerosis Genetics Consortium.

Cell. 2019 Jun 27;178(1):262. doi: 10.1016/j.cell.2019.06.016. No abstract available. Erratum in: Cell. 2020 Jan 23;180(2):403.

12.

Neurofilament Light Chain as a Biomarker in Multiple Sclerosis.

Varhaug KN, Torkildsen Ø, Myhr KM, Vedeler CA.

Front Neurol. 2019 Apr 5;10:338. doi: 10.3389/fneur.2019.00338. eCollection 2019. Review.

13.

Optimization of Receptor Occupancy Assays in Mass Cytometry: Standardization Across Channels with QSC Beads.

Bringeland GH, Bader L, Blaser N, Budzinski L, Schulz AR, Mei HE, Myhr KM, Vedeler CA, Gavasso S.

Cytometry A. 2019 Mar;95(3):314-322. doi: 10.1002/cyto.a.23723. Epub 2019 Jan 27.

14.

B cell depletion in the treatment of multiple sclerosis.

Myhr KM, Torkildsen Ø, Lossius A, Bø L, Holmøy T.

Expert Opin Biol Ther. 2019 Mar;19(3):261-271. doi: 10.1080/14712598.2019.1568407. Epub 2019 Jan 23. Review.

PMID:
30632834
15.

Shedding light on the link between early life sun exposure and risk of multiple sclerosis: results from the EnvIMS Study.

Magalhaes S, Pugliatti M, Riise T, Myhr KM, Ciampi A, Bjornevik K, Wolfson C.

Int J Epidemiol. 2019 Aug 1;48(4):1073-1082. doi: 10.1093/ije/dyy269.

PMID:
30561654
16.

Multiple sclerosis registries in Europe - An updated mapping survey.

Glaser A, Stahmann A, Meissner T, Flachenecker P, Horáková D, Zaratin P, Brichetto G, Pugliatti M, Rienhoff O, Vukusic S, de Giacomoni AC, Battaglia MA, Brola W, Butzkueven H, Casey R, Drulovic J, Eichstädt K, Hellwig K, Iaffaldano P, Ioannidou E, Kuhle J, Lycke K, Magyari M, Malbaša T, Middleton R, Myhr KM, Notas K, Orologas A, Otero-Romero S, Pekmezovic T, Sastre-Garriga J, Seeldrayers P, Soilu-Hänninen M, Stawiarz L, Trojano M, Ziemssen T, Hillert J, Thalheim C.

Mult Scler Relat Disord. 2019 Jan;27:171-178. doi: 10.1016/j.msard.2018.09.032. Epub 2018 Oct 4. No abstract available.

PMID:
30384204
17.

Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk.

International Multiple Sclerosis Genetics Consortium. Electronic address: chris.cotsapas@yale.edu; International Multiple Sclerosis Genetics Consortium.

Cell. 2018 Nov 29;175(6):1679-1687.e7. doi: 10.1016/j.cell.2018.09.049. Epub 2018 Oct 18.

18.

Serum levels of leptin and adiponectin are not associated with disease activity or treatment response in multiple sclerosis.

Kvistad SS, Myhr KM, Holmøy T, Benth JŠ, Wergeland S, Beiske AG, Bjerve KS, Hovdal H, Midgard R, Sagen JV, Torkildsen Ø.

J Neuroimmunol. 2018 Oct 15;323:73-77. doi: 10.1016/j.jneuroim.2018.07.011. Epub 2018 Jul 24.

PMID:
30196837
19.

Neurofilaments and 10-year follow-up in multiple sclerosis.

Bhan A, Jacobsen C, Myhr KM, Dalen I, Lode K, Farbu E.

Mult Scler. 2018 Sep;24(10):1301-1307. doi: 10.1177/1352458518782005. Epub 2018 Aug 1.

PMID:
30066611
20.

α-Linolenic acid is associated with MRI activity in a prospective cohort of multiple sclerosis patients.

Bjornevik K, Myhr KM, Beiske A, Bjerve KS, Holmøy T, Hovdal H, Midgard R, Riise T, Wergeland S, Torkildsen Ø.

Mult Scler. 2019 Jun;25(7):987-993. doi: 10.1177/1352458518779925. Epub 2018 Jun 4.

PMID:
29862891
21.

Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting.

Trojano M, Butzkueven H, Kappos L, Wiendl H, Spelman T, Pellegrini F, Chen Y, Dong Q, Koendgen H, Belachew S; Tysabri® Observational Program (TOP) Investigators.

Mult Scler Relat Disord. 2018 Aug;24:11-19. doi: 10.1016/j.msard.2018.04.020. Epub 2018 May 2.

22.

The economic impact of multiple sclerosis to the patients and their families in Norway.

Svendsen B, Grytten N, Bø L, Aarseth H, Smedal T, Myhr KM.

Eur J Health Econ. 2018 Dec;19(9):1243-1257. doi: 10.1007/s10198-018-0971-5. Epub 2018 Apr 21.

PMID:
29680926
23.

Severe multiple sclerosis reactivation after gonadotropin treatment.

Torkildsen Ø, Holmøy T, Myhr KM.

Mult Scler Relat Disord. 2018 May;22:38-40. doi: 10.1016/j.msard.2018.02.031. Epub 2018 Mar 6.

PMID:
29525298
24.

Fourteen sequence variants that associate with multiple sclerosis discovered by meta-analysis informed by genetic correlations.

Olafsson S, Stridh P, Bos SD, Ingason A, Euesden J, Sulem P, Thorleifsson G, Gustafsson O, Johannesson A, Geirsson AJ, Thorsson AV, Sigurgeirsson B, Ludviksson BR, Olafsson E, Kristjansdottir H, Jonasson JG, Olafsson JH, Orvar KB, Benediktsson R, Bjarnason R, Kristjansdottir S, Gislason T, Valdimarsson T, Mikaelsdottir E, Sigurdsson S, Jonsson S, Rafnar T, Aarsland D, Djurovic S, Fladby T, Knudsen GP, Celius EG, Myhr KM, Grondal G, Steinsson K, Valdimarsson H, Bjornsson S, Bjornsdottir US, Bjornsson ES, Nilsson B, Andreassen OA, Alfredsson L, Hillert J, Kockum IS, Masson G, Thorsteinsdottir U, Gudbjartsson DF, Stefansson H, Hjaltason H, Harbo HF, Olsson T, Jonsdottir I, Stefansson K.

NPJ Genom Med. 2017 Aug 8;2:24. doi: 10.1038/s41525-017-0027-2. eCollection 2017.

25.

Progressive multifocal leukoencephalopathy.

Alstadhaug KB, Myhr KM, Rinaldo CH.

Tidsskr Nor Laegeforen. 2017 Dec 12;137(23-24). doi: 10.4045/tidsskr.16.1092. Print 2017 Dec 12. Review. English, Norwegian.

26.

Neurofilament light chain predicts disease activity in relapsing-remitting MS.

Varhaug KN, Barro C, Bjørnevik K, Myhr KM, Torkildsen Ø, Wergeland S, Bindoff LA, Kuhle J, Vedeler C.

Neurol Neuroimmunol Neuroinflamm. 2017 Nov 28;5(1):e422. doi: 10.1212/NXI.0000000000000422. eCollection 2018 Jan.

27.

Antibody response to seasonal influenza vaccination in patients with multiple sclerosis receiving immunomodulatory therapy.

Olberg HK, Eide GE, Cox RJ, Jul-Larsen Å, Lartey SL, Vedeler CA, Myhr KM.

Eur J Neurol. 2018 Mar;25(3):527-534. doi: 10.1111/ene.13537. Epub 2018 Jan 6.

PMID:
29205701
28.

Break-out session highlights.

Myhr KM, Mäurer M, Ginés MM, Esposito F, Linker R.

Neurodegener Dis Manag. 2017 Nov;7(6s):45-49. doi: 10.2217/nmt-2017-0042.

PMID:
29143586
29.

The prevalence and characteristics of epilepsy in patients with multiple sclerosis in Nordland county, Norway.

Benjaminsen E, Myhr KM, Alstadhaug KB.

Seizure. 2017 Nov;52:131-135. doi: 10.1016/j.seizure.2017.09.022. Epub 2017 Oct 6.

30.

An update on cladribine for relapsing-remitting multiple sclerosis.

Holmøy T, Torkildsen Ø, Myhr KM.

Expert Opin Pharmacother. 2017 Oct;18(15):1627-1635. doi: 10.1080/14656566.2017.1372747. Epub 2017 Sep 11. Review.

PMID:
28858531
31.

1,25-Dihydroxyvitamin-D3 induces brain proteomic changes in cuprizone mice during remyelination involving calcium proteins.

Oveland E, Nystad A, Berven F, Myhr KM, Torkildsen Ø, Wergeland S.

Neurochem Int. 2018 Jan;112:267-277. doi: 10.1016/j.neuint.2017.08.008. Epub 2017 Aug 14.

PMID:
28818673
32.

Sodium intake and multiple sclerosis activity and progression in BENEFIT.

Fitzgerald KC, Munger KL, Hartung HP, Freedman MS, Montalbán X, Edan G, Wicklein EM, Radue EW, Kappos L, Pohl C, Ascherio A; BENEFIT Study Group.

Ann Neurol. 2017 Jul;82(1):20-29. doi: 10.1002/ana.24965.

33.

Survival and cause of death in multiple sclerosis: a 60-year longitudinal population study.

Lunde HMB, Assmus J, Myhr KM, Bø L, Grytten N.

J Neurol Neurosurg Psychiatry. 2017 Aug;88(8):621-625. doi: 10.1136/jnnp-2016-315238. Epub 2017 Apr 1.

34.

Body size and physical exercise, and the risk of multiple sclerosis.

Cortese M, Riise T, Bjørnevik K, Myhr KM; Multiple Sclerosis Conscript Service Database Study Group.

Mult Scler. 2018 Mar;24(3):270-278. doi: 10.1177/1352458517699289. Epub 2017 Mar 13.

PMID:
28287051
35.

Physical activity is associated with a decreased multiple sclerosis risk: The EnvIMS study.

Wesnes K, Myhr KM, Riise T, Cortese M, Pugliatti M, Boström I, Landtblom AM, Wolfson C, Bjørnevik K.

Mult Scler. 2018 Feb;24(2):150-157. doi: 10.1177/1352458517694088. Epub 2017 Feb 1.

PMID:
28273774
36.

Increased levels of cell-free mitochondrial DNA in the cerebrospinal fluid of patients with multiple sclerosis.

Varhaug KN, Vedeler CA, Myhr KM, Aarseth JH, Tzoulis C, Bindoff LA.

Mitochondrion. 2017 May;34:32-35. doi: 10.1016/j.mito.2016.12.003. Epub 2016 Dec 23.

PMID:
28017684
37.

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.

Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L; OPERA I and OPERA II Clinical Investigators.

N Engl J Med. 2017 Jan 19;376(3):221-234. doi: 10.1056/NEJMoa1601277. Epub 2016 Dec 21.

38.

CSF-PR 2.0: An Interactive Literature Guide to Quantitative Cerebrospinal Fluid Mass Spectrometry Data from Neurodegenerative Disorders.

Guldbrandsen A, Farag Y, Kroksveen AC, Oveland E, Lereim RR, Opsahl JA, Myhr KM, Berven FS, Barsnes H.

Mol Cell Proteomics. 2017 Feb;16(2):300-309. doi: 10.1074/mcp.O116.064477. Epub 2016 Nov 27.

39.

Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts.

Berger T, Elovaara I, Fredrikson S, McGuigan C, Moiola L, Myhr KM, Oreja-Guevara C, Stoliarov I, Zettl UK.

CNS Drugs. 2017 Jan;31(1):33-50. doi: 10.1007/s40263-016-0394-8. Review.

40.

The Brain Proteome of the Ubiquitin Ligase Peli1 Knock-Out Mouse during Experimental Autoimmune Encephalomyelitis.

Lereim RR, Oveland E, Xiao Y, Torkildsen Ø, Wergeland S, Myhr KM, Sun SC, Berven FS.

J Proteomics Bioinform. 2016 Sep;9(9):209-219. Epub 2016 Sep 12.

41.

In-Depth Cerebrospinal Fluid Quantitative Proteome and Deglycoproteome Analysis: Presenting a Comprehensive Picture of Pathways and Processes Affected by Multiple Sclerosis.

Kroksveen AC, Guldbrandsen A, Vaudel M, Lereim RR, Barsnes H, Myhr KM, Torkildsen Ø, Berven FS.

J Proteome Res. 2017 Jan 6;16(1):179-194. doi: 10.1021/acs.jproteome.6b00659. Epub 2016 Oct 26.

PMID:
27728768
42.

Negative interaction between smoking and EBV in the risk of multiple sclerosis: The EnvIMS study.

Bjørnevik K, Riise T, Bostrom I, Casetta I, Cortese M, Granieri E, Holmøy T, Kampman MT, Landtblom AM, Magalhaes S, Pugliatti M, Wolfson C, Myhr KM.

Mult Scler. 2017 Jun;23(7):1018-1024. doi: 10.1177/1352458516671028. Epub 2016 Sep 23.

PMID:
27663872
43.

The influence of coping styles on long-term employment in multiple sclerosis: A prospective study.

Grytten N, Skår AB, Aarseth JH, Assmus J, Farbu E, Lode K, Nyland HI, Smedal T, Myhr KM.

Mult Scler. 2017 Jun;23(7):1008-1017. doi: 10.1177/1352458516667240. Epub 2016 Sep 6.

PMID:
27600114
44.

Preclinical disease activity in multiple sclerosis: A prospective study of cognitive performance prior to first symptom.

Cortese M, Riise T, Bjørnevik K, Bhan A, Farbu E, Grytten N, Hogenesch I, Midgard R, Smith Simonsen C, Telstad W, Ascherio A, Myhr KM.

Ann Neurol. 2016 Oct;80(4):616-24. doi: 10.1002/ana.24769.

PMID:
27554176
45.

The 11-year long-term follow-up study from the randomized BENEFIT CIS trial.

Kappos L, Edan G, Freedman MS, Montalbán X, Hartung HP, Hemmer B, Fox EJ, Barkhof F, Schippling S, Schulze A, Pleimes D, Pohl C, Sandbrink R, Suarez G, Wicklein EM; BENEFIT Study Group.

Neurology. 2016 Sep 6;87(10):978-87. doi: 10.1212/WNL.0000000000003078. Epub 2016 Aug 10.

46.

No association of tobacco use and disease activity in multiple sclerosis.

Kvistad S, Myhr KM, Holmøy T, Benth JŠ, Løken-Amsrud KI, Wergeland S, Beiske AG, Bjerve KS, Hovdal H, Lilleås F, Midgard R, Pedersen T, Bakke SJ, Torkildsen Ø.

Neurol Neuroimmunol Neuroinflamm. 2016 Jul 14;3(4):e260. doi: 10.1212/NXI.0000000000000260. eCollection 2016 Aug.

47.

Level of education and multiple sclerosis risk over a 50-year period: Registry-based sibling study.

Bjørnevik K, Riise T, Benjaminsen E, Celius EG, Dahl OP, Kampman MT, Løken-Amsrud KI, Midgard R, Myhr KM, Torkildsen Ø, Vatne A, Grytten N.

Mult Scler. 2017 Feb;23(2):213-219. doi: 10.1177/1352458516646863. Epub 2016 Jul 11.

48.

Allelic imbalance of multiple sclerosis susceptibility genes IKZF3 and IQGAP1 in human peripheral blood.

Keshari PK, Harbo HF, Myhr KM, Aarseth JH, Bos SD, Berge T.

BMC Genet. 2016 Apr 14;17:59. doi: 10.1186/s12863-016-0367-4.

49.

Vitamin D, HLA-DRB1 and Epstein-Barr virus antibody levels in a prospective cohort of multiple sclerosis patients.

Wergeland S, Myhr KM, Løken-Amsrud KI, Beiske AG, Bjerve KS, Hovdal H, Midgard R, Kvistad SS, Holmøy T, Riise T, Torkildsen Ø.

Eur J Neurol. 2016 Jun;23(6):1064-70. doi: 10.1111/ene.12986. Epub 2016 Mar 21.

PMID:
26998820
50.

Label-free analysis of human cerebrospinal fluid addressing various normalization strategies and revealing protein groups affected by multiple sclerosis.

Opsahl JA, Vaudel M, Guldbrandsen A, Aasebø E, Van Pesch V, Franciotta D, Myhr KM, Barsnes H, Berle M, Torkildsen Ø, Kroksveen AC, Berven FS.

Proteomics. 2016 Apr;16(7):1154-65. doi: 10.1002/pmic.201500284.

PMID:
26841090

Supplemental Content

Loading ...
Support Center